Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | CES1 | P23141 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115280 | 0.85 | CES2 (0.50) | CES2CES1MEN1KMT2ACYP1A2 | |
| SCHEMBL29571616 | 0.85 | CES2 (0.50) | CES2CES1MEN1KMT2ACYP1A2 | |
| SCHEMBL18360859 | 0.83 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP3A4GRM1 | |
| SCHEMBL18361419 | 0.83 | MEN1 (0.50) | MEN1KMT2ACYP1A2CYP3A4GRM1 | |
| Hydrochloric Acid SCHEMBL20491499 | 0.83 | CES2 (0.49) | CES2CES1MEN1KMT2ACYP1A2 | |
| SCHEMBL9004079 | 0.83 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP3A4GRM1 | |
| SCHEMBL9004077 | 0.83 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP3A4GRM1 | |
| Hydrochloric Acid SCHEMBL23148270 | 0.81 | MEN1 (0.49) | CES2CES1MEN1KMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL23148269 | 0.81 | MEN1 (0.49) | CES2CES1MEN1KMT2ACYP1A2 | |
| SCHEMBL17847415 | 0.81 | DGAT1 (0.44) | MEN1KMT2ACYP1A2CYP3A4GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551859-B | Aza condensed ring amide compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-115160311-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-116115618-A | Medicine for treating tumor | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4151635-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551859-A | Aza condensed ring amide compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | ROS1, ALK, ROR1 | CES2 4179/4885CES1 2267/4885MEN1 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.